UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
Biopool International, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
- --------------------------------------------------------------------------------
(Title of Class of Securities)
90649104
- --------------------------------------------------------------------------------
(CUSIP Number)
Mr W Randolph, Biotech International Limited, PO Box 391 Acacia Ridge Qld 4110
Australia Tel: +61-7-3370-6396 Fax: +61-7-3370-6370
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
December 9, 1999
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check
the following box. [ ]
<PAGE>
CUSIP No. 90649104
- --------------------------------------------------------------------------------
1. Names of Reporting Persons. I.R.S. Identification Nos. of above
persons (entities only).
Biotech International Limited
- --------------------------------------------------------------------------------
2. Check the Appropriate Box if a Member of a Group (See Instructions)
(a) |_|
(b) |_|
- --------------------------------------------------------------------------------
3. SEC Use Only
- --------------------------------------------------------------------------------
4. Source of Funds WC BK
- --------------------------------------------------------------------------------
5. Check if Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e) |_|
- --------------------------------------------------------------------------------
6. Citizenship or Place of Organization
Australia
- --------------------------------------------------------------------------------
Number of Shares Beneficially Owned by Each Reporting Person With
7. Sole Voting Power
492,700
- --------------------------------------------------------------------------------
8. Shared Voting Power
- --------------------------------------------------------------------------------
9. Sole Dispositive Power
492,700
- --------------------------------------------------------------------------------
10. Shared Dispositive Power
- --------------------------------------------------------------------------------
11. Aggregate Amount Beneficially Owned by Each Reporting Person
492,700
- --------------------------------------------------------------------------------
12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions) |_|
- --------------------------------------------------------------------------------
13. Percent of Class Represented by Amount in Row (11)
5.95%
- --------------------------------------------------------------------------------
14. Type of Reporting Person
CO
- --------------------------------------------------------------------------------
2
<PAGE>
CUSIP No. 90649104 Schedule 13D
Item 1. Security and Issuer
This statement relates to Common Stock, par value $0.01 per share (the "Common
Stock") of Biopool International, Inc, a Delaware corporation (the "Issuer").
The Issuer's principal executive offices are located at 6025 Nicolle Street
Ventura, CA 93003.
Item 2. Identity and Background
The name, place of organization and business address of the person filing this
Statement is:
Biotech International Limited, a corporation organized under the laws of
Australia ("Biotech International"), of 11 Durbell Street Acacia Ridge
Queensland 4110 Australia.
Biotech International develops, manufactures and sells human and veterinary
diagnostics. It also is in the process of developing an industrial paper bleach
enzyme for eventual manufacture and sale. Its operations are based in Australia.
In its last fiscal year a large proportion of its sales of products were to
overseas markets.
The name, principal occupation, business address and citizenship of each of the
executive officers and directors of Biotech International are as follows:
Mr David R Fawcett (Chairman), Company Director, 11 Flannan Place Warwick
Western Australia 6024 , Citizen of Australia.
Mr Clive Little (Deputy Chairman), Company Director, 123 Gipps Street East
Melbourne Victoria 3002 Australia, Citizen of Australia.
3
<PAGE>
Mr Neville J Bassett (Director), Corporate Consultant, 23 Priory Road Maida Vale
Western Australia 6057 Australia, Citizen of Australia.
Mr Peter M Dowding (Director), Barrister at Law, 32 Kinninmont Avenue Nedlands
Western Australia 6009 Australia, Citizen of Australia.
Mr Roman Zwolenski (Executive Director), Company Manager, 50a Broomfield Street
Taringa Queensland 4068 Australia, Citizen of Australia.
Mr Warren A Randolph (Company Secretary), Corporate Consultant & CPA, 34
Fleetwood Street Macgregor Queensland 4109 Australia, Citizen of Australia.
Neither Biotech International nor, to the best of the knowledge of Biotech
International, any of its executive officers or directors has, during the last
five years, (a) been convicted in a criminal proceeding (excluding traffic
violations or similar misdemeanors) or (b) been a party to a civil proceeding of
a judicial or administrative body of competent jurisdiction and as a result of
such proceeding was or is subject to a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal
or state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration
All of the Common Stock acquired by Biotech International has been purchased on
the OTC Bulletin Board market on various dates.
Biotech International acquired the Common Stock with a combination of cash on
hand and borrowed funds. The borrowed funds were loaned to Biotech International
in the ordinary course of business pursuant to a general credit facility
provided to Biotech International by the Australia and New Zealand Banking Group
Limited.
Item 4. Purpose of Transaction
Biotech International acquired the Common Stock of the Issuer to gain an
investment interest in the Issuer.
In the course of strategic planning, Biotech International has determined to
increase its investment in the Issuer.
Biotech International reserves the right to exercise any and all of its rights
and privileges as a security holder of the Issuer. However, except as set forth
in this Item 4, Biotech International has no present plan or proposal that
relates to or would result in (i) the disposition of securities of the Issuer by
any person, (ii) an extraordinary corporate transaction, such as a merger,
reorganization, liquidation, or sale or transfer of a material amount of assets
involving the Issuer or any of its subsidiaries, (iii) any material change in
the Issuer's present capitalization or dividend policy or any other material
change in the Issuer's business or corporate structure, (iv) any change in the
Issuer's charter or bylaws or other actions that may impede the acquisition of
control of the Issuer by any person, (vi) a class of equity securities of the
Issuer becoming eligible for termination of
4
<PAGE>
registration pursuant to Section 12(g)(4) of the Securities Exchange Act of
1934, as amended, or a class of securities of the Issuer ceasing to be
authorized to be quoted in an inter-dealer quotation system of a registered
national securities association or (vi) any similar action.
Item 5. Interest in Securities of the Issuer
(a) and (b) Biotech International currently has ownership of 492,700 shares of
Common Stock of the Issuer. This amount constitutes approximately
5.95% of the issued and outstanding shares of Common Stock of the
Issuer, based upon the total of 8,286,986 issued and outstanding
shares as of December 15, 1999. Biotech International has the sole
power to direct the vote of and sole power to direct the disposition
of the 492,700 shares of Common Stock.
(c) During the past 60 days, Biotech International has made the following
purchases of Common Stock of the Issuer on the OTC Bulletin Board:
Date Common Stock purchased Price paid each
- ---- ---------------------- ---------------
October 29, 1999 15,000 81.250 cents
November 1, 1999 15,000 81.250 cents
November 4, 1999 10,000 84.375 cents
November 5, 1999 36,850 84.375 cents
November 10, 1999 23,500 87.500 cents
November 12, 1999 10,000 87.500 cents
November 12, 1999 27,500 90.625 cents
November 12, 1999 2,500 90.000 cents
November 16, 1999 10,000 90.000 cents
November 17, 1999 25,000 86.875 cents
November 18, 1999 20,000 89.063 cents
November 23, 1999 11,500 90.353 cents
November 26, 1999 97,500 90.625 cents
November 29, 1999 5,000 90.625 cents
December 1, 1999 9,350 90.625 cents
December 2, 1999 5,000 93.750 cents
December 3, 1999 21,500 92.660 cents
December 9, 1999 20,000 93.750 cents
December 10, 1999 10,000 87.500 cents
December 10, 1999 15,000 90.625 cents
December 13, 1999 10,000 90.625 cents
December 14, 1999 40,000 90.625 cents
(d) No other person is known to have the right to receive or the power to direct
the receipt of dividends from, or the proceeds from the sale of, the Common
Stock held by Biotech International.
(e) Not applicable.
5
<PAGE>
Item 6. Contracts, Arrangements, Understandings or Relationships with
Respect to Securities of the Issuer.
None
Item 7. Material to be Filed as Exhibits
None
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated December 15, 1999
Signature: /s/ Warren A. Randolph
---------------------------------
Name/Title: Warren A Randolph, Company Secretary, Biotech International Limited
